Three months of Wegovy: what actually happens to your body

Month one: your body is still adjusting, and that is the point

Imagine the box arrives, plain, no branding, DPD tracking having pinged your phone an hour earlier. Inside is a pre-filled pen, and the first dose is 0.25mg. That number surprises a lot of people. It feels symbolic rather than therapeutic, and in a sense it is: the first four weeks exist to let your gut, your gallbladder and your appetite signals adapt before the dose does any serious work. The semaglutide is already slowing gastric emptying and signalling fullness to the brain, but at 0.25mg the effect is gentle enough that most people notice it only as a mild reduction in portion size or hunger between meals.

Side effects in month one cluster in the days after the injection. Nausea is the most commonly reported, followed by burping, loose stools or constipation, sometimes alternating. The NHS medicines page on semaglutide describes this profile clearly: GI symptoms are expected, typically mild to moderate, and tend to ease as the body acclimatises. Eating smaller portions, staying hydrated and avoiding rich fatty meals helps. Weight loss in this first month is modest for most people. That is normal. The dose is doing its job of tolerability, not yet its job of treatment.

After four weeks, a prescriber reviews your response before any increase. The step to 0.5mg follows, and the same pattern repeats, a short adjustment period, then relative calm.

Month two: the dose is climbing and so are the results

By weeks five to eight, most people are moving through the 0.5mg to 1.0mg steps. Appetite suppression becomes more noticeable. Cravings (particularly for ultra-processed foods) often diminish in ways that feel qualitatively different from willpower-based restraint. Many people describe eating less simply because they want less. The STEP 1 trial, published in the New England Journal of Medicine, followed adults on semaglutide 2.4mg for 68 weeks alongside lifestyle support and found an average weight reduction of around 15%. The losses in months two and three, while the dose is still building, represent a meaningful proportion of that total trajectory.

This is also the month where the titration demands patience. Some people feel they are stepping up too slowly; others are relieved by it. A prescriber decides when it is appropriate to increase, and that clinical oversight is not a formality. If side effects are significant at 1.0mg, the standard schedule can be paused and the dose held for an extra four weeks, guidance from NHS England's weight management injections resource acknowledges this flexibility.

For people curious about how a longer horizon compares, our six-month Wegovy page covers what the evidence shows once the maintenance dose is fully established. The picture at three months is incomplete by design, the medicine is still ramping.

Month three: approaching the 1.7mg step and what that means

Weeks nine to twelve typically bring the move from 1.0mg to 1.7mg, the final step before the 2.4mg maintenance dose. For many people this is the moment the treatment starts to feel decisive. Appetite changes become harder to ignore. Energy levels often stabilise after the early GI turbulence, and the combination of reduced intake and improved satiety can produce a clearer sense of momentum.

At this point in the Wegovy titration schedule, most clinical guidance recommends paying particular attention to protein intake and hydration. When appetite falls sharply, total calories can drop quickly, and eating enough protein to preserve muscle mass matters. A prescriber or dietitian is best placed to advise on individual targets.

Side effects at 1.7mg can briefly resurface in the adjustment period, mirroring the pattern from earlier steps. Most people find them less disruptive than the initial weeks, partly familiarity, partly the body's adaptation. If you want to understand how the two-month journey compares in its own right, the two-month Wegovy page sets out that window in detail. And if you are considering oral semaglutide rather than the injection, the titration schedule and expected timeline differ in ways worth understanding before you start.

Checking whether Wegovy is the right option for your situation is the first step. You can start a free consultation with our prescribers to have your history and eligibility reviewed, the same day, by a real clinician.

What the three-month mark does and does not tell you

Three months of Wegovy is genuinely significant, but it is a progress report rather than a final result. The full 2.4mg dose (and for some people the newer 7.2mg option approved by the MHRA in early 2026) is typically only reached around week sixteen or later, and our five months on Wegovy page shows how results continue to develop once the maintenance dose has had time to work. The weight loss that trial data describe at 68 weeks continues to accumulate well beyond month three.

What the three-month window does tell you is whether you are tolerating the titration well, whether appetite changes are meaningful and whether the approach is sustainable alongside your diet and activity patterns. A clinical review at this point is not about deciding whether to stop, it is about understanding what the next phase looks like.

People sometimes ask how three months on Wegovy compares to three months on tirzepatide. The head-to-head SURMOUNT-5 trial data (covering a longer 72-week window) showed greater average weight loss with tirzepatide than with semaglutide 2.4mg, though both produced substantial results. A prescriber can help you weigh the options based on your full picture. Our semaglutide at three months page covers the broader evidence context, and the weight loss treatment overview explains how different medicines are assessed and prescribed. If you have questions about how the process works at nume, our FAQs are a good place to start, or you can read more about who we are and the standards we hold ourselves to.